# Nivolumab Combined With SOX Used in the Perioperative Treatment

> **NCT05739045** · PHASE2 · RECRUITING · sponsor: **Xiangdong Cheng** · enrollment: 46 (estimated)

## Conditions studied

- Immune Suppression
- Gastric Cancer

## Interventions

- **DRUG:** nivolumab combined with SOX

## Key facts

- **NCT ID:** NCT05739045
- **Lead sponsor:** Xiangdong Cheng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-03
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05739045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05739045, "Nivolumab Combined With SOX Used in the Perioperative Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05739045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*